Studies of floating dosage forms of furosemide: In vitro and in vivo evaluations of bilayer tablet formulations

Drug Development and Industrial Pharmacy

Volumn 26, Issue 8, 2000, Pages 857-866

  Özdemir, Nurten ^a   Ordu, Sefika ^a   Özkan, Yalçin ^b  

^a ANKARA UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Bioavailability; Controlled release; Floating dosage forms; Furosemide; Solid dispersion

Indexed keywords

FUROSEMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG SOLUBILITY; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; TABLET FORMULATION;

BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DIURETICS; DOSAGE FORMS; FUROSEMIDE; HUMANS; INTESTINE, SMALL; MALE; MIDDLE AGED; POLYMERS; STOMACH; TABLETS;

EID: 0033935589     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-100101309     Document Type: Article

References (18)

1. H. M. Ingani, J. Timmermans, and A. J. Moes, Conception and in vivo investigation of peroral sustained release floating dosage forms with enhanced gastrointestinal transit, Int. J. Pharm., 35, 157-164 (1987).
2. P. R. Sheth and J. Tossounian, The hydrodynamically balanced system (HBS), a novel drug delivery system for oral use, Drug Dev. Ind. Pharm., 10(2), 313-339 (1984).
3. J. Timmermans and A. J. Moes, How well do floating dosage forms float. Int. J. Pharm., 62, 207-216 (1990).
4. A. A. Deshpande, C. T. Rhodes, N. H. Shah, and A. W Malick, Controlled-release drug delivery systems for prolonged gastric residence: an overview, Drug Dev. Ind. Pharm., 22(6), 531-539 (1996).
5. A. Ebihara, K. Tawara, and T. Oka, Pharmacodynamic and pharmacokinetics study of a slow-release formulation of furosemide in man, Arzneim. Forsch./Drug Res., 33, 163-166 (1983).
6. O. Gohary and S. Gamal, Release of furosemide from sustained release microcapsules prepared by phase separation technique. Drug Dev. Ind. Pharm., 17(3), 443-450 (1991).
7. V. S. Chungi, L. W. Ditter, and B. S. Randal, Gastrointestinal sites of furosemide absorption in rats, Int. J. Pharm., 4, 27-38 (1979).
8. J. R. Robinson and S. P. Eriksen, Theoretical formulation of sustained release dosage forms, J. Pharm. Sci., 55, 1254-1263 (1966).
9. S. Waller, S. F. Hamilton, J. W. Massarella, M. A. Sharanevych, R. V. Smith, G. J. Yakatan, and J. T. Doluisio, Disposition and absolute bioavailability of furosemide in healthy males, J. Pharm. Sci., 71, 1105-1108 (1982).
10. M. M. Hammarlund, L. K. Paalzow, and B. Odlind, Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis, Eur. J. Clin. Pharniacol., 26, 197-207 (1984).
11. N. Özdemir and S. Ordu, Improvement of dissolution properties of furosemide by the complexation with β-cyclodextrin, Drug Dev. Ind. Pharm., 24(1), 19-25 (1998).
12. R. M. Jiménez Castellanos, H. Zia, and T. C. Rhodes, Dosing and testing in-vitro of a bioadhesive and floating drug delivery system for oral application. Int. J. Pharm., 105, 65-70 (1994).
13. U.S. Pharmacopeial Convention, The United States Pharmacopeia 23, Author, Rockville, MD, 1995, p. 2053.
14. T. Higuchi, Mechanism of sustained action medication, J. Pharm. Sci., 52, 1145-1149 (1963).
15. F. Langenbucher, Parametric representation of dissolution rate curves by the RRSBW distribution, Pharm. Ind., 38, 472-477 (1976).
16. B. Lindström, Determination of furosemide concentrations in plasma and urine using high-speed liquid chromatography, J. Chromatogr., 100, 189-191 (1974).
17. K. Carr, A. Rane, and J. C. Frölich, A simplified assay of furosemide in plasma and urine by high-pressure liquid chromatography, J. Chromatogr., 145, 421-427 (1978).
18. P. Colombo, D. Provasi, M. G. Borazzo, L. Maggi, and P. L. Catellani, The role of compression force in floating tablet formula optimization, Acta Pharm. Technol., 35(3), 168-170 (1989).